Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancers|December 11, 2022
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative ReviewGiuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, et al.
Cancers|January 8, 2023
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal TumorsAlessandra Dimino, Chiara Brando, Laura Algeri, et al.
Critical Reviews in Oncology/Hematology|October 20, 2024
Scientific Communication and oncology - "The bridge between knowledge and patients"Antonio Galvano, Andrea Gottardo, Valerio Gristina, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|June 1, 2024
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancerAndrea Gottardo, Tancredi Didier Bazan Russo, Alessandro Perez, et al.
Cancer Treatment Reviews|November 8, 2023
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, et al.
Frontiers in Oncology|May 4, 2023
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumabLorena Incorvaia, Alessandra Dimino, Laura Algeri, et al.
The Oncologist|July 18, 2023
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort StudyLorena Incorvaia, Dario De Biase, Margherita Nannini, et al.
The Journal of Liquid Biopsy|January 19, 2026
Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societiesValerio Gristina, Umberto Malapelle, Gennaro Daniele, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.
Pageof 6